Roberts Glore & Co. Inc. IL Acquires New Position in Quest Diagnostics Incorporated $DGX

Roberts Glore & Co. Inc. IL acquired a new stake in Quest Diagnostics Incorporated (NYSE:DGX) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 11,349 shares of the medical research company’s stock, valued at approximately $2,405,000.

A number of other institutional investors have also bought and sold shares of DGX. BlackRock Inc. purchased a new stake in Quest Diagnostics in the 2nd quarter valued at $1,965,923,000. Norges Bank acquired a new stake in shares of Quest Diagnostics in the 4th quarter worth $229,522,000. Boston Partners raised its holdings in shares of Quest Diagnostics by 32.8% during the 3rd quarter. Boston Partners now owns 4,036,881 shares of the medical research company’s stock worth $767,978,000 after acquiring an additional 997,033 shares during the period. EdgePoint Investment Group Inc. boosted its position in shares of Quest Diagnostics by 95.5% during the 4th quarter. EdgePoint Investment Group Inc. now owns 1,661,072 shares of the medical research company’s stock valued at $288,246,000 after acquiring an additional 811,320 shares during the last quarter. Finally, Legal & General Group Plc purchased a new stake in shares of Quest Diagnostics in the second quarter valued at about $151,986,000. 88.06% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

DGX has been the topic of a number of analyst reports. Jefferies Financial Group reaffirmed a “buy” rating and set a $245.00 target price on shares of Quest Diagnostics in a research note on Thursday, July 23rd. JPMorgan Chase & Co. raised their price target on shares of Quest Diagnostics from $220.00 to $250.00 and gave the stock a “neutral” rating in a report on Tuesday, July 28th. Robert W. Baird lifted their price target on shares of Quest Diagnostics from $236.00 to $255.00 and gave the company a “neutral” rating in a research report on Friday, July 24th. Weiss Ratings upgraded Quest Diagnostics from a “buy (b+)” rating to a “buy (a-)” rating in a report on Wednesday, August 12th. Finally, Argus set a $260.00 target price on Quest Diagnostics in a research note on Wednesday, July 29th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and seven have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $235.31.

Quest Diagnostics Trading Up 0.3%

NYSE DGX opened at $244.59 on Wednesday. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.59 and a quick ratio of 1.46. The stock has a market capitalization of $27.00 billion, a P/E ratio of 25.96, a PEG ratio of 2.25 and a beta of 0.56. The firm’s 50-day moving average is $221.07 and its two-hundred day moving average is $206.09. Quest Diagnostics Incorporated has a 12 month low of $171.18 and a 12 month high of $246.00.

Quest Diagnostics (NYSE:DGX) last announced its quarterly earnings results on Thursday, July 23rd. The medical research company reported $3.12 earnings per share for the quarter, beating analysts’ consensus estimates of $2.82 by $0.30. The business had revenue of $3.04 billion during the quarter, compared to analysts’ expectations of $2.97 billion. Quest Diagnostics had a net margin of 9.18% and a return on equity of 16.01%. The business’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same period last year, the business earned $2.62 earnings per share. Quest Diagnostics has set its FY 2026 guidance at 11.050-11.250 EPS. On average, sell-side analysts anticipate that Quest Diagnostics Incorporated will post 11.15 earnings per share for the current year.

Quest Diagnostics Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 21st. Investors of record on Tuesday, October 6th will be issued a $0.86 dividend. This represents a $3.44 annualized dividend and a yield of 1.4%. The ex-dividend date is Tuesday, October 6th. Quest Diagnostics’s dividend payout ratio (DPR) is 36.52%.

Insider Buying and Selling at Quest Diagnostics

In other Quest Diagnostics news, SVP Karthik Kuppusamy sold 8,147 shares of the business’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $200.00, for a total value of $1,629,400.00. Following the sale, the senior vice president owned 13,510 shares of the company’s stock, valued at $2,702,000. The trade was a 37.62% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Mark E. Delaney sold 1,600 shares of the company’s stock in a transaction on Tuesday, July 28th. The stock was sold at an average price of $235.18, for a total value of $376,288.00. Following the transaction, the senior vice president owned 10,335 shares in the company, valued at $2,430,585.30. This trade represents a 13.41% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 19,747 shares of company stock valued at $3,947,088 over the last quarter. 0.88% of the stock is owned by company insiders.

Quest Diagnostics Profile

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.